See more : Osool and Bakheet Investment Co. (9586.SR) Income Statement Analysis – Financial Results
Complete financial analysis of Sawai Group Holdings Co., Ltd. (SWGHF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sawai Group Holdings Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Ferrexpo plc (FEEXY) Income Statement Analysis – Financial Results
- Hana Microelectronics Public Company Limited (HNMUF) Income Statement Analysis – Financial Results
- Australasian Metals Limited (A8G.AX) Income Statement Analysis – Financial Results
- BingEx Limited (FLX) Income Statement Analysis – Financial Results
- Daiwa Co.,Ltd. (8247.T) Income Statement Analysis – Financial Results
Sawai Group Holdings Co., Ltd. (SWGHF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.sawaigroup.holdings
About Sawai Group Holdings Co., Ltd.
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. The company offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, granules, capsules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, anti-cancer, chemotherapeutic agents, etc., as well as vitamin preparations. It sells its generic drugs to distributors, wholesalers, and retailers in Japan and the United States. The company was founded in 1929 and is headquartered in Osaka, Japan.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 176.86B | 200.34B | 193.82B | 187.22B | 182.54B | 184.34B | 168.07B | 132.39B | 123.49B | 105.45B | 89.82B | 80.50B |
| Cost of Revenue | 122.54B | 137.71B | 127.16B | 114.79B | 109.04B | 109.44B | 102.87B | 81.47B | 72.68B | 60.05B | 48.35B | 42.51B |
| Gross Profit | 54.32B | 62.63B | 66.65B | 72.43B | 73.50B | 74.90B | 65.20B | 50.92B | 50.81B | 45.41B | 41.47B | 37.99B |
| Gross Profit Ratio | 30.71% | 31.26% | 34.39% | 38.69% | 40.27% | 40.63% | 38.79% | 38.46% | 41.14% | 43.06% | 46.17% | 47.19% |
| Research & Development | 12.19B | 16.09B | 24.41B | 13.88B | 13.49B | 16.67B | 14.53B | 7.24B | 8.02B | 6.11B | 5.17B | 4.55B |
| General & Administrative | 23.24B | 30.16B | 46.69B | 0.00 | 0.00 | 0.00 | 26.65B | 18.26B | 17.53B | 15.80B | 14.57B | 13.82B |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.83B | 2.07B | 2.07B | 2.10B | 2.02B | 1.62B |
| SG&A | 23.24B | 30.16B | 46.69B | 39.94B | 33.38B | 32.38B | 28.49B | 20.34B | 19.61B | 17.90B | 16.58B | 15.44B |
| Other Expenses | 266.00M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 35.70B | 46.25B | 71.10B | 53.82B | 46.86B | 49.05B | 43.02B | 27.58B | 27.62B | 25.06B | 22.51B | 20.13B |
| Cost & Expenses | 158.24B | 183.96B | 198.27B | 168.61B | 155.90B | 158.49B | 145.89B | 109.05B | 100.31B | 85.11B | 70.86B | 62.64B |
| Interest Income | 201.00M | 18.00M | 2.00M | 138.00M | 295.00M | 322.00M | 51.00M | 1.00M | 266.00M | 48.00M | 30.00M | 231.00M |
| Interest Expense | 558.00M | 406.00M | 460.00M | 502.00M | 558.00M | 529.00M | 1.13B | 286.00M | 386.00M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 18.06B | 17.68B | 17.05B | 18.29B | 17.95B | 16.28B | 14.24B | 8.52B | 7.04B | 5.86B | 4.99B | 3.79B |
| EBITDA | 36.88B | 33.93B | -18.70B | 36.91B | 44.59B | 42.13B | 36.42B | 31.87B | 30.23B | 26.55B | 24.08B | 21.15B |
| EBITDA Ratio | 20.85% | 17.01% | 6.50% | 19.71% | 24.43% | 22.85% | 21.67% | 24.07% | 24.48% | 25.18% | 26.81% | 26.27% |
| Operating Income | 18.62B | 16.39B | -4.45B | 18.61B | 26.64B | 25.85B | 22.18B | 23.35B | 23.19B | 20.69B | 19.09B | 17.36B |
| Operating Income Ratio | 10.53% | 8.18% | -2.30% | 9.94% | 14.59% | 14.02% | 13.19% | 17.63% | 18.77% | 19.62% | 21.25% | 21.56% |
| Total Other Income/Expenses | -358.00M | 402.00M | -31.76B | -154.00M | -141.00M | -182.00M | -1.93B | -590.00M | -94.00M | -392.00M | -102.00M | 738.00M |
| Income Before Tax | 18.26B | 16.79B | -36.21B | 18.46B | 26.50B | 25.67B | 20.25B | 22.76B | 23.09B | 20.30B | 18.99B | 18.10B |
| Income Before Tax Ratio | 10.33% | 8.38% | -18.68% | 9.86% | 14.52% | 13.92% | 12.05% | 17.19% | 18.70% | 19.25% | 21.14% | 22.48% |
| Income Tax Expense | 5.58B | 3.95B | 5.71B | 7.61B | 6.72B | 5.94B | 6.14B | 4.79B | 5.94B | 6.24B | 6.80B | 6.08B |
| Net Income | 13.70B | 12.67B | -28.27B | 12.34B | 19.28B | 19.38B | 14.02B | 17.97B | 17.16B | 14.05B | 12.19B | 12.02B |
| Net Income Ratio | 7.74% | 6.32% | -14.59% | 6.59% | 10.56% | 10.51% | 8.34% | 13.57% | 13.89% | 13.33% | 13.57% | 14.93% |
| EPS | 229.60 | 289.26 | -645.54 | 281.81 | 440.35 | 442.63 | 360.49 | 487.39 | 465.55 | 381.85 | 330.41 | 318.17 |
| EPS Diluted | 311.80 | 288.61 | -645.54 | 281.52 | 439.98 | 442.33 | 360.27 | 487.10 | 465.24 | 381.85 | 331.61 | 320.65 |
| Weighted Avg Shares Out | 59.65M | 43.79M | 43.79M | 43.79M | 43.78M | 43.78M | 38.88M | 36.87M | 36.85M | 36.80M | 36.90M | 37.78M |
| Weighted Avg Shares Out (Dil) | 43.92M | 43.89M | 43.79M | 43.83M | 43.82M | 43.80M | 38.91M | 36.89M | 36.87M | 36.80M | 36.77M | 37.49M |
Source: https://incomestatements.info
Category: Stock Reports